Kymera Therapeutics is a clinical stage biopharmaceutical company that is developing novel protein degrader therapeutics for treating disease in effective new ways, which harness the body’s natural protein degradation system to selectively degrade disease causing proteins with the goal of removing them from the body. Kymera Therapeutics is driven to invent transformative medicines for a broad variety of diseases where traditional drug modalities have failed to adequately unlock the appropriate biological solution.
The company is pioneering a transformative new modality, “targeted protein degradation” (TPD), with the capability to pursue targets long considered undruggable and to treat disease in new ways. Its mission is to discover, develop and commercialize novel and transformative therapies to better the lives of patients with serious diseases.
Its team has developed a proprietary drug discovery engine, Pegasus, to allow the design of highly selective, small molecule protein degraders with potent activity against a wide range of disease indications. The company is committed to selecting targets with the widest possible impact across multiple disease indications with unmet medical need to realize the full potential of TPD.